Further studies on whether CYP3A4*22, or other SNPs of CYP3A4, could affect the experience of hot flashes would be worthwhile, contributing further evidence on whether CYP3A4*22 can be used as a biomarker to regulate this symptom among breast cancer patients undergoing adjuvant endocrine therapies. This evidence concerns the gene CYP3A4 and breast cancer.